Table 4 Treatment related adverse events
From: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports
| Â | Â | Number (%) with outcome | Â | ||
|---|---|---|---|---|---|
Dosing (mg) | Number of trials | Sildenafil | Placebo | Relative risk (95% CI) | NNH (95% CI) |
25 | 3 | 71/312 (23) | 33/426 (8) | 2.8 (1.9 to 4.2) | 6.7 (4.9 to 10) |
50 | 5 | 190/508 (37) | 59/607 (10) | 3.7 (2.8 to 4.8) | 3.6 (3.1 to 4.4) |
100 | 5 | 260/506 (51) | 59/607 (10) | 5.0 (3.9 to 6.5) | 2.4 (2.2 to 2.7) |
200 | 2 | 137/191 (72) | 26/181 (14) | 5.0 (3.5 to 7.2) | 1.7 (1.5 to 2.0) |
Dose optimised | 5 | 155/517 (30) | 60/524 (11) | 2.6 (2.0 to 3.4) | 5.4 (4.3 to 7.3) |